Vertex Pharmaceuticals, Inc.

Viro Chem Pharma, Inc.

Biochem Pharma Inc.

Monica Bubenik

Laval Chan Chun Kong

Louis Vaillancourt

Christophe Moinet

Oswy Z Pereira

Marc Courchesne

Constantin G Yannopoulos

Carl Poisson

Bingcan Liu

Guy Falardeau

Caroline Cadilhac

Jian Jim Wang

Albert Charles Pierce

John Patrick Maxwell

Kevin Michael Cottrell

Govinda Rao Bhisetti

Simon Giroux

Mark A Morris

James A Henderson

Sanjoy Kumar Das

Ronald Lee Grey, Jr

Valerie Marone

T Jagadeeswar Reddy

Charles Blais

Luc J Farmer

Youssef L Bennani

Boulos Zacharie

Claudio F Sturino

Giorgio Attardo

Yeeman K Ramtohul

Frederic Vallee

Julien Martel

Serge Lamothe

Jean-Eric Lacoste

Youssef Laafiret Bennani

Liliane Halab

Janek Szychowski

Denis Labrecque

Stephanie Lessard

Réal Denis

Miguel St-Onge

Nathalie Chauret

Paul Nguyen-Ba

Laval Chan

Bingan Liu

Nathalie Turcotte

Camil Elie Sayegh

Sylvie Charron

Patrice Pr&eacute;ville

R&eacute;al Denis

Pierre-Andre Fournier

The present invention relates to compounds useful as inhibitors of the PAR-2 signaling pathway. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of GPCRs in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such GPCRs; and the comparative evaluation of new inhibitors of the PAR-2 signaling pathway. The compounds of this invention have formula I: wherein the variables are as defined herein.

Imidazopyridazines useful as inhibitors of the PAR-2 signaling pathway

Compounds represented by formula I: or pharmaceutically acceptable salts and solvates thereof, wherein A, B, B', X, Y, R, R&#x2032;, R, R&#x2032;, R, R&#x2032;, R, R&#x2032;, R, m, n, or p are as defined herein, are useful for treating flaviviridae viral infections.

Benzimidazole analogues for the treatment or prevention of flavivirus infections

The invention relates to 21-keto triterpene compounds of formula (I): wherein R, X, and Y are as defined herein, and pharmaceutically acceptable salts and solvates thereof. These compounds exhibit significant anti-HIV activity. Thus, the invention also relates to methods for prevention or treatment of HIV infections by administering therapeutically effective amounts of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof to a subject in need of such treatment. 

Lupane derivatives useful for treating HIV

Compounds according to formula (I): wherein R, R, R, n and X are defined as defined herein, and the pharmaceutically acceptable salts, hydrates and solvates thereof, are useful for the modulation of CCR5 chemokine receptor activity. Additionally, compounds according to Formula III: wherein Z, R', and R&#x2032;are defined as defined herein, and the pharmaceutically acceptable salts, hydrates and solvates thereof, are useful as intermediates for production of compounds that modulate CCR5 chemokine receptor activity.

Spirotropane compounds

Compounds according to formula (I): wherein A, Rand Rare as defined herein, and the pharmaceutically acceptable salts, hydrates and solvates thereof are useful for the modulation of CCR5 chemokine receptor activity.

Spirotropane compounds and methods for the modulation of chemokine receptor activity

Compounds according to formula (I): wherein A, R, Rand Rare defined as defined herein, and the pharmaceutically acceptable salts, hydrates and solvates thereof, are useful for the modulation of CCR5 chemokine receptor activity.

Novel compounds represented by formula (I): wherein R, R, Rand Rare as defined herein, and pharmaceutically acceptable salts, hydrates and solvates thereof, are useful for the modulation of CCR5 chemokine receptor activity.

Spirohydantoin compounds and methods for the modulation of chemokine receptor activity

The present invention comprises compounds that are effective inhibitors of integrins, particularly &agr;v&bgr;3 and &agr;v&bgr;5 integrins. Particularly, the compounds are of formula I

Thiophene integrin inhibitors

Growing community of inventors

Mascouche, Canada

Monica Bubenik